Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT06958393Phase 4Not yet recruiting
Phase 4, randomised trial of dexmedetomidine, esmolol and esketamine in postoperative delirium (POD) (2 arms), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: Incidence of Postoperative Delirium at 7 days. Planned start May 2025; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT06958393.